Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union
Enrico Costa(Brigham and Women's Hospital), Hubert G. M. Leufkens(Utrecht University), Silvia Girotti(University of Verona), Carlo Castellani(Cystic Fibrosis Research Foundation), Clément Mathieu(Université de Bordeaux), Joseph S. Ross(Yale University), Jennifer L. Taylor‐Cousar(National Jewish Health)
Cited by 6
Related Papers
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis
|Nature Genetics|2006|250
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications
|European Journal of Clinical Pharmacology|2014|162
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
AI, Health, and Health Care Today and Tomorrow
|JAMA|2025|95
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
|Journal of Cystic Fibrosis|2024|77